Skip To Main Content
Baoqi Yang on Muck Rack

Baoqi Yang

As seen in: Nature, Frontiers in Immunology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Baoqi Yang’s profile

Articles by Baoqi Yang

Targeting an IL-17/IL-36 pathogenic hub in hidradenitis suppurativa with a bispecific antibody

|
By Yonghu Sun, Zihao Mi, Yueqian Yu, Zhenzhen Wang, Lele Sun, Jianke Li, Baoqi Yang, Xiuhuan Wang, Yilei Wu, Kexin Liu, Xiaochen Ren, Jing J. Liu, Hong Luan, Guowei Zhao, Jian Shi, Chi Ma, Yongxia Liu, Mingkai Zhang, Peng Song, Peng Qu, Jianfeng Wang, Na Wang, Yue Xin, Qingqing Guo, Weizhi Wu, Hongqing Tian, Xuehui Li, Guoyuan Peng, Xuan Guo, Guangliang Zhang, Benke Li, Xiaoxiao Yan, Jianwen Wang, Jiabao You, Gongqi Yu, Chuan Wang, Xiaopei Cui, Yifan Zhan, Xiangyang Zhu, Hong liu, Furen Zhang, Minkuo Zhang, Wenwen Sai, Xiuqiang Ma
| Nature Verified
Abstract Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder with a high unmet need, particularly for treatment-resistant tunnels. Integrated multiomics analysis revealed that HS tunnels are spatially organized, self-amplifying inflammatory circuits driven by synergistic IL-17/IL-36γ activation of a unique keratinocyte subset, which activates neutrophils and inflammatory fibroblasts.
Open in Who Shared Issue with article?

Case Report: Nicotinamide monotherapy for infantile bullous pemphigoid with long-term follow-up

|
By Peng Qu, Guizhi Zhou, Baoqi Yang
| Frontiers in Immunology
Abstract Infantile bullous pemphigoid (IBP) is a rare autoimmune bullous skin disease that occurs in infants, for which standardized targeted therapeutic regimens remain unavailable. Herein, we report two infants with IBP treated with nicotinamide monotherapy. Complete clinical remission was observed within 3 weeks and 10 days after treatment initiation, respectively. Following clinical improvement, nicotinamide was gradually tapered and discontinued in approximately 2 months.
Open in Who Shared Issue with article?
Show More